ICUI - Earnings announcements

SAN CLEMENTE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2026. First Quarter 2026 Results The following year-over-year results reflect the strategic divestiture of the IV Solutions business on May 1, 2025. First quarter 2026 GAAP revenue declined 12% year-over-year; however, excluding the impact of the IV Solutions divestiture and foreign currency, non-GAAP organic revenue increased 1%. First quarter 2026 GAAP revenue was $530.2 million, as compared to $604.7 million in the same period in the prior yea

SAN CLEMENTE, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2026 earnings release and conference call. The Company will release its first quarter 2026 results on Thursday, May 7, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 7, 2026. The call can be accessed at 1-800-343-4136, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websit

SAN CLEMENTE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2025. Fourth Quarter 2025 Results Fourth quarter 2025 revenue was $540.7 million, as compared to $629.8 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2025 was $203.0 million, as compared to $227.3 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2025 was 38%, as compared to 36% in the same period in the prior year. GAAP net loss for the fourth quarter of 2025

SAN CLEMENTE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2025 earnings release and conference call. The Company will release its fourth quarter 2025 results on Thursday, February 19, 2026 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, February 19, 2026. The call can be accessed at (800) 274-8461, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com

SAN CLEMENTE, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2025. Third Quarter 2025 Results Third quarter 2025 revenue was $537.0 million, as compared to $589.1 million in the same period in the prior year. GAAP gross profit for the third quarter of 2025 was $200.9 million, as compared to $204.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2025 was 37%, as compared to 35% in the same period in the prior year. GAAP net loss for the third quarter of 2025 was

SAN CLEMENTE, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2025 earnings release and conference call. The Company will release its third quarter 2025 results on Thursday, November 6, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, November 6, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company

SAN CLEMENTE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2025. Second Quarter 2025 Results Second quarter 2025 revenue was $548.9 million, as compared to $596.5 million in the same period in the prior year. GAAP gross profit for the second quarter of 2025 was $208.1 million, as compared to $207.4 million in the same period in the prior year. GAAP gross margin for the second quarter of 2025 was 38%, as compared to 35% in the same period in the prior year. GAAP net income for the second quarter of 202

SAN CLEMENTE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2025 earnings release and conference call. The Company will release its second quarter 2025 results on Thursday, August 7, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, August 7, 2025. The call can be accessed at (800) 267-6316, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2025 earnings release and conference call. The Company will release its first quarter 2025 results on Thursday, May 8, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 8, 2025. The call can be accessed at (800) 225-9448, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's webs

SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024. Fourth Quarter 2024 Results Fourth quarter 2024 revenue was $629.8 million, as compared to $587.9 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2024 was $227.3 million, as compared to $171.6 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2024 was 36.1%, as compared to 29.2% in the same period in the prior year. GAAP net loss for the fourth quarter of 2

SAN CLEMENTE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2024 earnings release and conference call. The Company will release its fourth quarter 2024 results on Thursday, February 27, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, February 27, 2025. The call can be accessed at (800) 445-7795, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com

SAN CLEMENTE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended September 30, 2024. Third Quarter 2024 Results Third quarter 2024 revenue was $589.1 million, as compared to $553.3 million in the same period in the prior year. GAAP gross profit for the third quarter of 2024 was $204.9 million, as compared to $183.9 million in the same period in the prior year. GAAP gross margin for the third quarter of 2024 was 34.8%, as compared to 33.2% in the same period in the prior year. GAAP net loss for the third quarter of 2024

SAN CLEMENTE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2024 earnings release and conference call. The Company will release its third quarter 2024 results on Tuesday, November 12th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, November 12th, 2024. The call can be accessed at (800) 343-5172, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Com

SAN CLEMENTE, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended June 30, 2024. Second Quarter 2024 Results Second quarter 2024 revenue was $596.5 million, compared to $549.3 million in the same period in the prior year. GAAP gross profit for the second quarter of 2024 was $207.4 million, as compared to $192.3 million in the same period in the prior year. GAAP gross margin for the second quarter of 2024 and 2023 was 35%. GAAP net loss for the second quarter of 2024 was $(21.4) million, or $(0.88) per diluted share, as c

SAN CLEMENTE, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2024 earnings release and conference call. The Company will release its second quarter 2024 results on Wednesday, August 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, August 7th, 2024. The call can be accessed at (800) 579-2543, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the C

SAN CLEMENTE, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2024. First Quarter 2024 Results First quarter 2024 revenue was $566.7 million, compared to $568.6 million in the same period in the prior year. GAAP gross profit for the first quarter of 2024 was $185.2 million, as compared to $192.0 million in the same period in the prior year. GAAP gross margin for the first quarter of 2024 was 33%, as compared to 34% in the same period in the prior year. GAAP net loss for the first quarter of 2024 was $(39.5)

SAN CLEMENTE, Calif., April 23, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2024 earnings release and conference call. The Company will release its first quarter 2024 results on Tuesday, May 7th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, May 7th, 2024. The call can be accessed at (800) 717-1738, conference ID 1112534. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websi

SAN CLEMENTE, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2023. Fourth Quarter 2023 Results Fourth quarter 2023 revenue was $587.9 million, compared to $578.0 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2023 was $171.6 million, as compared to $174.9 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2023 was 29%, as compared to 30% in the same period in the prior year. GAAP net loss for the fourth quarter of 2023

SAN CLEMENTE, Calif., Feb. 13, 2024 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2023 earnings release and conference call. The Company will release its fourth quarter 2023 results on Tuesday, February 27th, 2024 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Tuesday, February 27th, 2024. The call can be accessed at (833) 816-1376, conference ID 10186026. The conference call will be simultaneously available by webcast, which can be accessed by going to the

SAN CLEMENTE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended September 30, 2023. Third Quarter 2023 Results Third quarter 2023 revenue was $553.3 million, compared to $597.9 million in the same period last year. GAAP gross profit for the third quarter of 2023 was $183.9 million, as compared to $186.4 million in the same period last year. GAAP gross margin for the third quarter of 2023 was 33%, as compared to 31% in the same period last year. GAAP net income for the third quarter of 2023 was $7.2 million, or $0.30 per diluted

SAN CLEMENTE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2023 earnings release and conference call. The Company will release its third quarter 2023 results on Monday, November 6th, 2023 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, November 6th, 2023. The call can be accessed at (833) 816-1376, conference ID 10182943. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company

SAN CLEMENTE, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2023. Second Quarter 2023 Results Second quarter 2023 revenue was $549.3 million, compared to $561.0 million in the same period last year. GAAP gross profit for the second quarter of 2023 was $192.3 million, as compared to $167.6 million in the same period last year. GAAP gross margin for the second quarter of 2023 was 35%, as compared to 30% in the same period last year. GAAP net loss for the second quarter of 2023 was $(9.9) million,

SAN CLEMENTE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2023 earnings release and conference call. The Company will release its second quarter 2023 results on Monday, August 7th, 2023 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, August 7th, 2023. The call can be accessed at (833) 816-1376, conference ID 10180958. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company

SAN CLEMENTE, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended March 31, 2023. First Quarter 2023 Results First quarter 2023 revenue was $568.6 million, compared to $543.1 million in the same period last year. GAAP gross profit for the first quarter of 2023 was $192.0 million, as compared to $168.8 million in the same period last year. GAAP gross margin for the first quarter of 2023 was 34%, as compared to 31% in the same period last year. GAAP net loss for the first quarter of 2023 was $(9.8) million, or $(0.41) per diluted sh

SAN CLEMENTE, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2023 earnings release and conference call. The Company will release its first quarter 2023 results on Monday, May 8th, 2023 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, May 8th, 2023. The call can be accessed at (877) 300-8521, conference ID 10177448. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websit

SAN CLEMENTE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2022. Fourth Quarter 2022 Results Fourth quarter 2022 revenue was $578.0 million, compared to $340.5 million in the same period last year. GAAP gross profit for the fourth quarter of 2022 was $174.9 million, as compared to $127.5 million in the same period last year. GAAP gross margin for the fourth quarter of 2022 was 30%, as compared to 37% in the same period last year. GAAP net loss for the fourth quarter of 2022 was $(15.5) million, or

SAN CLEMENTE, Calif., Feb. 13, 2023 (GLOBE NEWSWIRE) --  ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2022 earnings release and conference call. The Company will release its fourth quarter 2022 results on Monday, February 27th, 2023 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, February 27th, 2023. The call can be accessed at (877) 300-8521, conference ID 10174731. The conference call will be simultaneously available by webcast, which can be accessed by going to the

SAN CLEMENTE, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended September 30, 2022. Third Quarter 2022 Results Third quarter 2022 revenue was $597.9 million, compared to $336.1 million in the same period last year. GAAP gross profit for the third quarter of 2022 was $186.4 million, as compared to $127.8 million in the same period last year. GAAP gross margin for the third quarter of 2022 was 31%, as compared to 38% in the same period last year. GAAP net loss for the third quar

SAN CLEMENTE, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its third quarter 2022 earnings release and conference call. The Company will release its third quarter 2022 results on Monday, November 7th, 2022 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, November 7th, 2022. The call can be accessed at (877) 300-8521, conference ID 10171949. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company

SAN CLEMENTE, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended June 30, 2022. Second Quarter 2022 Results Second quarter 2022 revenue was $561.0 million, compared to $321.7 million in the same period last year. GAAP gross profit for the second quarter of 2022 was $167.6 million, as compared to $123.5 million in the same period last year. GAAP gross margin for the second quarter of 2022 was 30%, as compared to 38% in the same period last year. GAAP net loss for the second quarter of 2022 was $(7.5) million, or $(0.31) p

SAN CLEMENTE, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its second quarter 2022 earnings release and conference call. The Company will release its second quarter 2022 results on Monday, August 8th, 2022 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, August 8th, 2022. The call can be accessed at (877) 300-8521, conference ID 10169518. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's

SAN CLEMENTE, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended March 31, 2022. First Quarter 2022 Results First quarter 2022 revenue was $543.1 million, compared to $318.0 million in the same period last year. GAAP gross profit for the first quarter of 2022 was $168.8 million, as compared to $112.7 million in the same period last year. GAAP gross margin for the first quarter of 2022 was 31%, as compared to 35% in the same period last year. GAAP net loss for the first quarter of 2022 was $(38.1) million, or $(1.61) per diluted s

SAN CLEMENTE, Calif., April 20, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2022 earnings release and conference call. The Company will release its first quarter 2022 results on Monday, May 9th, 2022 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Monday, May 9th, 2022. The call can be accessed at (877) 407-3982, conference ID 13729265. The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's websit

SAN CLEMENTE, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarter ended December 31, 2021. Fourth Quarter 2021 Results Fourth quarter 2021 revenue was $340.5 million, compared to $320.5 million in the same period last year. GAAP gross profit for the fourth quarter of 2021 was $127.5 million, as compared to $119.9 million in the same period last year. GAAP gross margin for the fourth quarter of 2021 was 37%, as compared to 37% in the same period last year. GAAP net income for the fourth quarter of 2021 was $19.9 million, or $0.91 per di

SAN CLEMENTE, Calif., Feb. 04, 2022 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its fourth quarter 2021 earnings release and conference call. The Company will release its fourth quarter 2021 results on Thursday, February 24th, 2022 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, February 24th, 2022. The call can be accessed at (855) 327-6837, conference ID 10017891. The conference call will be simultaneously available by webcast, which can be accessed by going to the

SAN CLEMENTE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended September 30, 2021. Third Quarter 2021 Results Third quarter 2021 revenue was $336.1 million, compared to $318.6 million in the same period last year. GAAP gross profit for the third quarter of 2021 was $127.8 million, as compared to $113.9 million in the same period last year. GAAP gross margin for the third quarter of 2021 was 38%, as compared to 36% in the same period last year. GAAP net income for the thir

SAN CLEMENTE, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced the time of its third quarter 2021 earnings release and conference call. The Company will release its third quarter 2021 results on Wednesday, November 3, 2021 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, November 3, 2021. The call can be accessed at (877) 407-3982.The conference call will be simultaneously available by webcast, which can be

The addition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products intoICU Medical creates a leading infusion therapy company with a stronger global reach Complementary product portfolios joined to create a leading IV therapy company and simplify customer workflowAddition of logical adjacencies to expand available marketsUnites two OUS operating footprints into a scaled global companyCreates a leading US-domiciled company to add diversity and resiliency to the medical supply chainAllows for multiple growth vectors through appealing products across hospital, alt site, pharmacy, and home Leverages significant investment into integration and infr

SAN CLEMENTE, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products used in infusion therapy and critical care applications, today announced financial results for the quarter ended June 30, 2021. Second Quarter 2021 Results Second quarter 2021 revenue was $321.7 million, compared to $303.4 million in the same period last year. GAAP gross profit for the second quarter of 2021 was $123.5 million, as compared to $106.3 million in the same period last year. GAAP gross margin for the second quarter of 2021 was 38%, as compared to 35% in the same period last year. GAAP net income for t